mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.
Company profile
Ticker
MEIP
Exchange
Website
CEO
Daniel Gold
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
MARSHALL EDWARDS INC
SEC CIK
Corporate docs
IRS number
510407811
MEIP stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
29 Feb 24
424B5
Prospectus supplement for primary offering
28 Feb 24
8-K
Other Events
21 Feb 24
S-3
Shelf registration
20 Feb 24
8-K
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
13 Feb 24
10-Q
2024 Q2
Quarterly report
13 Feb 24
8-K
Departure of Directors or Certain Officers
17 Jan 24
8-K
Changes in Registrant's Certifying Accountant
26 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
22 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
18 Dec 23
Latest ownership filings
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4/A
James P Flynn
12 Jan 24
4/A
Steven D Wood
12 Jan 24
4
Steven D Wood
20 Dec 23
4
James P Flynn
20 Dec 23
3
Steven D Wood
14 Nov 23
3
Taheer Datoo
6 Nov 23
3
James P Flynn
3 Nov 23
SC 13D/A
Anson Funds Management LP
1 Nov 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.37 mm | 3.37 mm | 3.37 mm | 3.37 mm | 3.37 mm | 3.37 mm |
Cash burn (monthly) | 4.51 mm | 940.08 k | (no burn) | (no burn) | 6.16 mm | 4.68 mm |
Cash used (since last report) | 30.63 mm | 6.38 mm | n/a | n/a | 41.85 mm | 31.80 mm |
Cash remaining | -27.26 mm | -3.01 mm | n/a | n/a | -38.48 mm | -28.43 mm |
Runway (months of cash) | -6.0 | -3.2 | n/a | n/a | -6.2 | -6.1 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 33 |
Opened positions | 6 |
Closed positions | 24 |
Increased positions | 1 |
Reduced positions | 22 |
13F shares | Current |
---|---|
Total value | 12.59 bn |
Total shares | 24.12 mm |
Total puts | 0.00 |
Total calls | 37.20 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Growth Equity Opportunities V | 9.96 mm | $17.93 mm |
Biotechnology Value Fund L P | 5.59 mm | $14.76 mm |
Vivo Opportunity | 3.30 mm | $8.71 mm |
Helsinn Investment Fund | 2.62 mm | $6.49 mm |
Anson Funds Management | 662.53 k | $4.36 bn |
Vanguard | 383.55 k | $2.52 bn |
Tang Capital Partners | 361.08 k | $1.74 mm |
Tang Capital Management | 361.08 k | $2.38 bn |
Acadian Asset Management | 230.55 k | $1.52 mm |
Renaissance Technologies | 144.75 k | $952.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Dec 23 | Steven D Wood | Stock Option Common Stock | Grant | Acquire A | No | No | 6.19 | 10,000 | 61.90 k | 10,000 |
18 Dec 23 | Steven D Wood | Stock Option Common Stock | Grant | Acquire A | No | No | 6.19 | 6,700 | 41.47 k | 6,700 |
18 Dec 23 | James P Flynn | Stock Option Common Stock | Grant | Acquire A | No | No | 6.19 | 10,000 | 61.90 k | 10,000 |
18 Dec 23 | James P Flynn | Stock Option Common Stock | Grant | Acquire A | No | No | 6.19 | 6,700 | 41.47 k | 6,700 |
News
Stifel Maintains Hold on MEI Pharma, Maintains $7 Price Target
12 Apr 24
MEI Pharma Aligns On Strategy To Advance Voruciclib And ME-344
11 Apr 24
MEI Pharma Reports Initial Data From Clinical Study Evaluating ME-344 In Combination With Bevacizumab In Relapsed Metastatic Colorectal Cancer Patients
11 Apr 24
5 Value Stocks In The Healthcare Sector
19 Feb 24
MEI Pharma Q2 2024 GAAP EPS $(1.66) Misses $(1.32) Estimate
13 Feb 24
Press releases
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
11 Apr 24
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
10 Apr 24
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
26 Mar 24
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
13 Feb 24